12:00 AM
 | 
Nov 18, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PUR0200: Phase Ib data

Data from 24 patients with moderate COPD in the first part of a 2-part, 5-way, double-blind, crossover, U.K. Phase Ib trial showed that single ascending-doses of PUR0200 were generally well tolerated and...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >